Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Can-Fite BioPharma ( (CANF) ) has issued an announcement.
On November 3, 2025, Can-Fite BioPharma Ltd. held a Special General Meeting of Shareholders, which was adjourned due to a lack of quorum. The meeting is rescheduled to reconvene on November 10, 2025, at the company’s offices in Ramat Gan, Israel. This adjournment may impact the company’s decision-making processes and timelines, potentially affecting its strategic operations and stakeholder interests.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Underperform.
The overall stock score for Can-Fite BioPharma is low due to significant financial challenges, bearish technical indicators, and lack of valuation data. The company’s declining revenues, persistent losses, and reliance on external financing are major concerns. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and in oversold conditions.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company based in Israel, specializing in the development of small molecule drugs for the treatment of autoimmune inflammatory diseases, cancer, and liver diseases.
Average Trading Volume: 193,041
Technical Sentiment Signal: Sell
Current Market Cap: $15.74M
For an in-depth examination of CANF stock, go to TipRanks’ Overview page.